Preceding Antithrombotic Treatment is Associated With Acute Ischemic Stroke Severity and Functional Outcome at 90 Days Among Patients With Atrial Fibrillation

被引:12
作者
Yi, Xingyang [1 ]
Lin, Jing [2 ]
Han, Zhao [3 ,4 ]
Luo, Hua [5 ]
Shao, Minjie [6 ]
Fan, Daofeng [7 ]
Zhou, Qiang [2 ]
机构
[1] Peoples Hosp Deyang City, Dept Neurol, Deyang, Sichuan, Peoples R China
[2] Wenzhou Med Univ, Affiliated Hosp 3, Dept Neurol, 108 Wansong Rd, Wenzhou 325200, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Dept Neurol, Affiliated Hosp 2, Wenzhou, Zhejiang, Peoples R China
[4] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China
[5] Southwest Med Univ, Affiliated Hosp, Dept Neurol, Luzhou, Sichuan, Peoples R China
[6] Wenzhou Med Univ, Affiliated Wenling Hosp, Dept Neurol, Wenzhou, Zhejiang, Peoples R China
[7] Fujian Med Univ, Dept Neurol, Affiliated Longyan Hosp 1, Longyan, Zhejiang, Peoples R China
关键词
Anticoagulation; atrial fibrillation; ischemic stroke; warfarin; stroke severity; outcome; HEALTH-CARE PROFESSIONALS; NEUROLOGICAL DETERIORATION; ORAL ANTICOAGULATION; PLATELET ACTIVITY; ELDERLY-PATIENTS; RISK-FACTORS; PREVENTION; WARFARIN; ASPIRIN; CHINA;
D O I
10.1016/j.jstrokecerebrovasdis.2019.03.028
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Antithrombotic therapies are known to prevent ischemic stroke (IS) for patients with atrial fibrillation (AF), but are often underused in clinical practice. The aim of present study was to investigate the prevalence of patients with acute IS with known history of AF who were not receiving antithrombotic treatment before stroke and to evaluate the association of preceding antithrombotic treatment with stroke severity and outcomes at 90 days after admission. Materials and Methods: This was a retrospective, multi-center, observational study of 748 patients with acute IS and known history of AF admitted to 6 participating hospitals between March 2016 and October 2017. The primary outcome was stroke severity at admission as assessed using National Institutes of Health Stroke Scale (NIHSS) score. The secondary outcome was functional outcome at 90 days after admission as measured by modified Rankin Scale (mRS) score. Results: A total of 748 patients, 54 (7.2%) were receiving therapeutic warfarin (international normalized ratio [INR] >= 2) and 100 (13.4%) had subtherapeutic warfarin anticoagulation (INR < 2), 340 (45.5%) were receiving antiplatelet treatment, and 254 (34.0%) were not receiving any antithrombotic treatment prior to stroke. Compared with no antithrombotic treatment, therapeutic warfarin (OR: 0.64; 95% CI: 0.52-0.82; P = .022), and antiplatelet therapy only (OR: 0.89; 95% CI: 0.76-0.96; P = .041) were associated with lower odds ratio of moderate or severe stroke (NIHSS >= 16). Patients receiving preceding therapeutic warfarin (OR: 1.32; 95% CI: 1.22-3.57; P = .025), antiplatelet therapy only (OR: 1.13; 95% CI: 1.07-2.59; P = .043), and subtherapeutic warfarin with INR 1.5 to 1.99 (OR: 1.15; 95% CI: 1.10-2.66; P = .042) had higher odds ratio of better functional outcome (mRS <= 2) at 90 days. Conclusions: Among patients with AF who had experienced an acute IS, inadequate therapeutic warfarin preceding the stroke was very prevalent in China. Therapeutic warfarin was associated with less severe stroke and better functional outcome at 90 days.
引用
收藏
页码:2003 / 2010
页数:8
相关论文
共 38 条
  • [1] Baseline NIH Stroke Scale score strongly predicts outcome after stroke - A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST)
    Adams, HP
    Davis, PH
    Leira, EC
    Chang, KC
    Bendixen, BH
    Clarke, WR
    Woolson, RF
    Hansen, MD
    [J]. NEUROLOGY, 1999, 53 (01) : 126 - 131
  • [2] Admission International Normalized Ratio and Acute Infarct Volume in Ischemic Stroke
    Ay, Hakan
    Arsava, Ethem Murat
    Gungor, Levent
    Greer, David
    Singhal, Aneesh B.
    Furie, Karen L.
    Koroshetz, Walter J.
    Sorensen, A. Gregory
    [J]. ANNALS OF NEUROLOGY, 2008, 64 (05) : 499 - 506
  • [3] National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation
    Dlott, Jeffrey S.
    George, Roberta A.
    Huang, Xiaohua
    Odeh, Mouneer
    Kaufman, Harvey W.
    Ansell, Jack
    Hylek, Elaine M.
    [J]. CIRCULATION, 2014, 129 (13) : 1407 - 1414
  • [4] WARFARIN IN THE PREVENTION OF STROKE ASSOCIATED WITH NONRHEUMATIC ATRIAL-FIBRILLATION
    EZEKOWITZ, MD
    BRIDGERS, SL
    JAMES, KE
    CARLINER, NH
    COLLING, CL
    GORNICK, CC
    KRAUSESTEINRAUF, H
    KURTZKE, JF
    NAZARIAN, SM
    RADFORD, MJ
    RICKLES, FR
    SHABETAI, R
    DEYKIN, D
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (20) : 1406 - 1412
  • [5] Use of oral anticoagulation among stroke patients with atrial fibrillation in China: the ChinaQUEST (Quality evaluation of stroke care and treatment) registry study
    Gao, Qingchun
    Fu, Xian
    Wei, Jade W.
    Chen, Xiangyan
    Huang, Yining
    Wang, Jiguang
    Anderson, Craig S.
    Wong, Ka Sing
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2013, 8 (03) : 150 - 154
  • [6] Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls
    Garwood, Candice L.
    Corbett, Tia L.
    [J]. ANNALS OF PHARMACOTHERAPY, 2008, 42 (04) : 523 - 532
  • [7] Edoxaban versus Warfarin in Patients with Atrial Fibrillation
    Giugliano, Robert P.
    Ruff, Christian T.
    Braunwald, Eugene
    Murphy, Sabina A.
    Wiviott, Stephen D.
    Halperin, Jonathan L.
    Waldo, Albert L.
    Ezekowitz, Michael D.
    Weitz, Jeffrey I.
    Spinar, Jindrich
    Ruzyllo, Witold
    Ruda, Mikhail
    Koretsune, Yukihiro
    Betcher, Joshua
    Shi, Minggao
    Grip, Laura T.
    Patel, Shirali P.
    Patel, Indravadan
    Hanyok, James J.
    Mercuri, Michele
    Vogelmann, O.
    Gonzalez, C.
    Ahuad Guerrero, R.
    Rodriguez, M.
    Albisu, J.
    Rosales, E.
    Allall, O.
    Reguero, M.
    Alvarez, C.
    Garcia, M.
    Ameriso, S.
    Ameriso, P.
    Amuchastegui, M.
    Caceres, M.
    Beloscar, J.
    Petrucci, J.
    Berli, M.
    Budassi, N.
    Valle, M.
    Bustamante Labarta, G.
    Saravia, M.
    Caccavo, A.
    Fracaro, V.
    Cartasegna, L.
    Novas, V.
    Caruso, O.
    Saa Zarandon, R.
    Colombo, H.
    Morandini, M.
    Cuello, J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (22) : 2093 - 2104
  • [8] Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated
    Gladstone, David J.
    Bui, Esther
    Fang, Jiming
    Laupacis, Andreas
    Lindsay, M. Patrice
    Tu, Jack V.
    Silver, Frank L.
    Kapral, Moira K.
    [J]. STROKE, 2009, 40 (01) : 235 - 240
  • [9] Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
    Go, AS
    Hylek, EM
    Phillips, KA
    Chang, YC
    Henault, LE
    Selby, JV
    Singer, DE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (18): : 2370 - 2375
  • [10] Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappa B activation
    Grilli, M
    Pizzi, M
    Memo, M
    Spano, P
    [J]. SCIENCE, 1996, 274 (5291) : 1383 - 1385